Skip to main content
Journal cover image

Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation.

Publication ,  Journal Article
Shetty, S; Wu, Y; Lloyd, CZ; Mehta, N; Liu, Y; Woodruff, ME; Segura, T; Collier, JH
Published in: Advanced healthcare materials
February 2025

IL-1β is a principal proinflammatory cytokine underlying multiple local and systemic chronic inflammatory conditions including psoriasis, rheumatoid arthritis, inflammatory bowel disease, and type 2 diabetes. Passive immunotherapies and biologic drugs targeting IL-1β, while offering significant clinical benefit, nevertheless have limitations such as significant non-response rates, induction of anti-drug antibodies, and high costs. Here, an active immunotherapy raising antibody responses against IL-1β employing self-assembling peptide nanofibers is described. The nanofibers contain defined quantities of B-cell epitopes from IL-1β and exogenous T helper epitopes and employ the Q11 self-assembling peptide platform. Without adjuvant, the nanofibers raised durable anti-IL-1β antibody responses that inhibit IL-1β activity in vitro and in vivo. In a mouse model of imiquimod-induced psoriasis, prophylactic immunizations with the nanofibers diminished symptoms of epidermal thickening. This therapeutic effect is associated with biasing the immune response toward an anti-inflammatory IgG1/Th2 phenotype and a lowered expression of proinflammatory genes in the skin. Further, anti-IL-1β nanofibers induced therapeutic immunosuppressive CD62L+ Treg cells. This technology represents a potential alternative for passive immunotherapies and other biologics for treating chronic inflammatory conditions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Advanced healthcare materials

DOI

EISSN

2192-2659

ISSN

2192-2640

Publication Date

February 2025

Volume

14

Issue

5

Start / End Page

e2401444

Related Subject Headings

  • Psoriasis
  • Peptides
  • Nanofibers
  • Mice, Inbred C57BL
  • Mice
  • Interleukin-1beta
  • Inflammation
  • Immunotherapy, Active
  • Imiquimod
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shetty, S., Wu, Y., Lloyd, C. Z., Mehta, N., Liu, Y., Woodruff, M. E., … Collier, J. H. (2025). Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation. Advanced Healthcare Materials, 14(5), e2401444. https://doi.org/10.1002/adhm.202401444
Shetty, Shamitha, Yaoying Wu, Christopher Z. Lloyd, Nalini Mehta, Yining Liu, Mia E. Woodruff, Tatiana Segura, and Joel H. Collier. “Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation.Advanced Healthcare Materials 14, no. 5 (February 2025): e2401444. https://doi.org/10.1002/adhm.202401444.
Shetty S, Wu Y, Lloyd CZ, Mehta N, Liu Y, Woodruff ME, et al. Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation. Advanced healthcare materials. 2025 Feb;14(5):e2401444.
Shetty, Shamitha, et al. “Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation.Advanced Healthcare Materials, vol. 14, no. 5, Feb. 2025, p. e2401444. Epmc, doi:10.1002/adhm.202401444.
Shetty S, Wu Y, Lloyd CZ, Mehta N, Liu Y, Woodruff ME, Segura T, Collier JH. Anti-Cytokine Active Immunotherapy Based on Supramolecular Peptides for Alleviating IL-1β-Mediated Inflammation. Advanced healthcare materials. 2025 Feb;14(5):e2401444.
Journal cover image

Published In

Advanced healthcare materials

DOI

EISSN

2192-2659

ISSN

2192-2640

Publication Date

February 2025

Volume

14

Issue

5

Start / End Page

e2401444

Related Subject Headings

  • Psoriasis
  • Peptides
  • Nanofibers
  • Mice, Inbred C57BL
  • Mice
  • Interleukin-1beta
  • Inflammation
  • Immunotherapy, Active
  • Imiquimod
  • Humans